Promising patient trials surrounding the medication Retatrutide , specifically the 120 milligram formulation branded as ZPHC, reveal a considerable impact on weight decrease and associated metabolic conditions . Researchers believe that this innovative compound, affecting both GLP-1 and GIP systems, has the potential to offer a substantial advance